Canadian Longitudinal Study
Amgen reports positive results from landmark cardiovascular study
The study found significant reductions of major cardiovascular events in high-risk adults following treatment
Lilly and WHO Foundation partner to support global dementia action plan
The partnership will provide financial support and strengthen early detection and intervention efforts
Lilly launches global Alzheimer’s campaign with Julianne Moore
The new ‘Brain Health Matters’ campaign urges the public to prioritise brain health
Eli Lilly’s Mounjaro shown to provide cardiovascular protection in type 2 diabetes patients
Approximately 38.4 million people in the US are affected by diabetes
Novartis and ProFound enter cardiovascular disease collaboration worth $750m per target
The companies will aim to discover and develop new therapeutics for the group of disorders
Eli Lilly to expand cardiovascular disease pipeline with $1.3bn Verve acquisition
The deal will give Lilly access to Verve’s pipeline of gene editing medicines for atherosclerotic CVD
NewAmsterdam’s CETP inhibitor obicetrapib shows promise in Alzheimer’s sub-study
The trial was primarily designed to assess the LDL-C lowering efficacy of the candidate
Novo Nordisk’s GLP-1 drug Wegovy shows early protection against heart disease
Heart and circulatory diseases are responsible for more than 170,000 deaths in the UK every year
Merck gains rights to Hengrui’s heart disease candidate in deal worth almost $2bn
Cardiovascular diseases result in an estimated 17.9 million global deaths each year
GSK to explore link between Shingrix and dementia risk in new UK research collaboration
More than 55 million people worldwide are currently living with the neurodegenerative disease
UK drug repurposing study identifies several potential dementia treatments
An estimated 982,000 people in the UK are currently living with the neurodegenerative disease
Eli Lilly shares positive results for modified titration of Alzheimer’s drug donanemab
The neurodegenerative disorder accounts for up to 75% of the 982,000 dementia cases in the UK